DPx Holdings B.V. Completes Acquisition of Gallus BioPharmaceuticals
News Oct 08, 2014
DPx Holdings B.V. has announced that it has completed the transaction to acquire Gallus BioPharmaceuticals, LLC, a leading contract manufacturing company specializing in biologics. Patheon’s biologic drug substance business, a unit of DPx Holdings, now spans four global facilities in Europe, Australia and North America and includes more than 550 employees.
“We are pleased to have closed this transaction within such a short period of time so that we can begin providing customers with an even higher level of service with our expanded service offerings and dedicated biologics presence in the U.S.,” says Jim Mullen, CEO of DPx Holdings. “This acquisition allows us to better serve the biologics segment in our industry and aligns with our strategy to continue to bring our customers an industry leading end-to-end service offering.”
The Patheon pharma services business provides commercial manufacturing, pharmaceutical product development services for a full array of solid and sterile dosage forms, and biologic and chemical drug substance development and manufacturing. With the Gallus BioPharmaceuticals acquisition, Patheon is now a leading provider of process development as well as clinical and commercial scale manufacturing of mammalian cell culture derived products.
Patheon offers customers a broad array of disposable manufacturing technology, as well as commercial scale production, throughout its expanded global network. In addition, Patheon is able to leverage its expertise in disposable technology to expedite manufacturing as well as broaden its capabilities in mid-scale flexible manufacturing. These enhanced capabilities further support the Patheon end-to-end integrated offering providing small-scale API and biologic drug substance through to commercial manufacturing.
The two existing Gallus sites in St. Louis, Mo. and Princeton, N.J. are the first Patheon biologic drug substance sites in the U.S. and complement the two existing sites in Groningen, the Netherlands and Brisbane, Australia.
Three of these four global sites each have nearly three decades of mammalian cell culture experience, while the fourth site in Brisbane was opened within the last year and is considered a facility of the future for biologics.
Under the Patheon brand, these sites will support the company’s continued expertise in biologics and support the needs of Patheon’s customers in this growing segment of the industry.
Autism Risk Higher if Pregnant Mothers Have Infection Requiring HospitalizationNews
Studies have shown that mothers who experience an infection severe enough to require hospitalization during pregnancy are at higher risk of having a child with autism.READ MORE
Flow Chemistry Process Development: Johnson Matthey and Snapdragon Chemistry Announce PartnershipNews
Johnson Matthey and Snapdragon Chemistry Inc. are pleased to announce that they have entered in to a collaborative agreement to provide integrated continuous manufacturing services – from development to full-scale GMP manufacturing.READ MORE
Ebola Vaccination: Study Assessing Immune Response Fuels Improved Vaccine DevelopmentNews
DZIF scientists were successful in their study, assessing early on, the longer-term immune response in humans after being vaccinated with the newly developed Ebola vaccine “rVSV-ZEBOV“.READ MORE